| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01837719 | Human Immunodeficiency Virus Type 1 (HIV-1) | Drug: Atazanavir|Drug: Cobicistat|Drug: Atazanavir/Cobicistat FDC | Bristol-Myers Squibb | Phase 1 | 2013-04-01 | 2014-08-19 |
| NCT00916448 | Endotoxemia|Inflammation|Multi Organ Dysfunction Syndrome|Sepsis | Drug: Atazanavir|Drug: E. coli endotoxin | Radboud University | | 2009-05-01 | 2015-08-13 |
| NCT00940771 | Pediatric HIV|HIV Infections | Drug: Boosted Atazanavir | Phoenix Children's Hospital|Bristol-Myers Squibb | Phase 4 | 2009-04-01 | 2015-10-21 |
| NCT01404572 | HIV | Drug: Atazanavir (current formulation)|Drug: Atazanavir, powder for oral use 1 (POU1)|Drug: Atazanavir (POU2) | Bristol-Myers Squibb | Phase 1 | 2011-08-01 | 2013-05-03 |
| NCT03019783 | HIV | Drug: Atazanavir|Other: Placebo | Brigham and Women's Hospital | Phase 2|Phase 3 | 2011-12-01 | 2017-01-11 |
| NCT01599364 | Human Immunodeficiency Virus | Drug: Atazanavir, ritonavir, lamivudine | Catholic University of the Sacred Heart | Phase 4 | 2014-04-01 | 2016-08-14 |
| NCT00357721 | HIV Infections|Protease Inhibitor | Drug: Atazanavir Sulphate|Drug: Atazanavir Sulphate|Drug: Atazanavir Sulphate | Bristol-Myers Squibb | Phase 1 | 2006-06-01 | 2011-04-05 |
| NCT02034838 | HIV Infection | Drug: atazanavir 300mg boosted with ritonavir 50 mg | Ottawa Hospital Research Institute|Bristol-Myers Squibb | Phase 1 | 2014-01-01 | 2015-09-21 |
| NCT00874523 | HIV Infection | Drug: atazanavir plus raltegravir|Drug: atazanavir plus raltegravir | Kirby Institute | Phase 3 | 2009-07-01 | 2012-04-10 |
| NCT00225017 | HIV Infection|Hyperlipidemia | Drug: Atazanavir|Drug: current antiretroviral regimen | Northwestern University|Bristol-Myers Squibb | Phase 3 | 2005-06-01 | 2012-06-29 |
| NCT01335698 | HIV | Drug: Atazanavir Sulphate|Drug: Ritonavir | Bristol-Myers Squibb | Phase 3 | 2011-05-01 | 2017-02-02 |
| NCT00357188 | HIV Infections|Protease Inhibitor | Drug: Atazanavir Sulphate + Ritonavir|Drug: Atazanavir Sulphate + Ritonavir + Efavirenz | Bristol-Myers Squibb | Phase 1 | 2006-07-01 | 2011-04-07 |
| NCT01759875 | Healthy | Drug: Ritonavir-boosted Atazanavir|Drug: Ritonavir-boosted Atazanavir plus Rabeprazole|Drug: Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride | University of California, San Francisco | Phase 1 | 2013-01-01 | 2015-04-24 |
| NCT00833482 | Human Immunodeficiency Virus Type 1 (HIV-1)|HIV Infections | Drug: Voriconazole|Drug: Atazanavir|Drug: Ritonavir | Bristol-Myers Squibb | Phase 1 | 2009-09-01 | 2012-09-24 |
| NCT01928407 | HIV-1 Infection|Immunosuppression-related Infectious Disease | Drug: DARUNAVIR|Drug: ATAZANAVIR | Institut de Mdecine et d'Epidmiologie Applique - Fondation Internationale Lon M'Ba | Phase 4 | 2011-03-01 | 2013-08-20 |
| NCT01691794 | HIV, Pediatric | Drug: Atazanavir|Drug: Ritonavir | Bristol-Myers Squibb | Phase 4 | 2012-11-01 | 2016-02-08 |
| NCT01099579 | HIV Infections | Drug: Atazanavir powder|Drug: Ritonavir oral solution|Drug: Atazanavir capsules|Drug: Ritonavir capsules | Bristol-Myers Squibb | Phase 3 | 2011-11-01 | 2017-02-02 |
| NCT00357604 | HIV Infections | Drug: Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)|Drug: Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days | Bristol-Myers Squibb | Phase 1 | 2006-07-01 | 2011-04-07 |
| NCT02102048 | HIV | Drug: Atazanavir | University of Roma La Sapienza | | 2009-01-01 | 2014-03-28 |
| NCT00413153 | HIV Infections | Drug: atazanavir/ritonavir|Drug: lopinavir/ritonavir | Massachusetts General Hospital|Bristol-Myers Squibb | 2006-05-01 | 2010-03-05 |
| NCT01232127 | HIV | Drug: Atazanavir|Drug: Atazanavir|Drug: Ritonavir|Drug: Ritonavir|Drug: Tenofovir (TDF)|Drug: Tenofovir (TDF)|Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Drug: Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Drug: Famotidine (FAM)|Drug: Famotidine (FAM) | Bristol-Myers Squibb | Phase 4 | 2011-02-01 | 2012-08-27 |
| NCT00224445 | HIV Infections | Drug: Truvada|Drug: Atazanavir|Drug: Ritonavir | Gilead Sciences | Phase 4 | 2005-09-01 | 2013-01-08 |
